Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the listing application of arginine ibuprofen, enhancing its product portfolio and market competitiveness in the chemical raw materials sector [1] Group 1 - The approval notification for arginine ibuprofen is a significant milestone for the company, as it is a non-steroidal anti-inflammatory drug with superior water solubility compared to regular ibuprofen [1] - Arginine ibuprofen offers faster absorption and quicker onset of action, which may appeal to healthcare providers and patients [1] - The approval enriches the company's product variety, potentially strengthening its competitive position in the chemical raw materials market [1]
亨迪药业：公司获得化学原料药精氨酸布洛芬上市申请批准通知书